Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 5;8(3):E15-E17.
doi: 10.1093/ehjcvp/pvac010.

Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19

Luis Ortega-Paz  1 , Mattia Galli  2 , Dominick J Angiolillo  1
Affiliations
Editorial

Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19

Luis Ortega-Paz et al. Eur Heart J Cardiovasc Pharmacother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forest plots of escalated-dose vs. standard-dose prophylactic anticoagulation in non-critically ill hospitalized patients with COVID-19 for all-cause death, major bleeding, and venous thromboembolism. CI, confidence interval; IV, inverse variance; M–H, Mantel–Haenszel; and VTE, venous thromboembolism.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Ortega-Paz L, Galli M, Capodanno D, Franchi F, Rollini F, Bikdeli B, Mehran R, Montalescot G, Gibson CM, Lopes RD, Andreotti F, Angiolillo DJ. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother;doi: 10.1093/ehjcvp/pvab070. Published online ahead of print 14 September 2021. - PMC - PubMed
    1. Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc 2021; 10:e019650. - PMC - PubMed
    1. Arevalos V, Ortega-Paz L, Rodriguez-Arias JJ, Calvo M, Castrillo L, Salazar A, Roque M, Dantas AP, Sabate M, Brugaletta S. Myocardial injury in COVID-19 patients: association with inflammation, coagulopathy and in-hospital prognosis. J Clin Med 2021;10:2096. - PMC - PubMed
    1. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI, HEP-COVID Investigators . Efficacy and safety of therapeutic-dose heparin vs. standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181:1612–1620. - PMC - PubMed
    1. Marcos-Jubilar M, Carmona-Torre F, Vidal R, Ruiz-Artacho P, Filella D, Carbonell C, Jiménez-Yuste V, Schwartz J, Llamas P, Alegre F, Sádaba B, Núñez-Córdoba J, Yuste JR, Fernández-García J, Lecumberri R; BEMICOP Investigators . Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022; 122:295–299. - PubMed